A
ArcherDX
Biotechnology firm specializing in cancer research
About ArcherDX
ArcherDX is a biotechnology company that specializes in genomic analysis for cancer research. The company provides a range of products and services designed to be accurate, personalized, and actionable for use in local laboratories.
Their core offering includes kits and software that enable researchers and clinicians to conduct targeted sequencing with greater speed and precision. These tools are used to identify known and novel fusion transcripts, which are important in cancer diagnostics. ArcherDX's platform is intended to make precision oncology more accessible.
The company serves researchers and clinicians in the oncology field. Their business model is based on the sale of these kits and software. ArcherDX was acquired by Invitae, a move that is expected to create a global leader in comprehensive cancer genetics and precision oncology.
Source: Dealroom company dataKnowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Boulder Ventures- PGPBM Capital Group
Perceptive Advisors- TFThe Peierls Foundation
Series B and later3 investors entered at this stage
Driehaus Capital Management
Redmile Group
ArrowMark Partners
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
11 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about ArcherDX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ArcherDX on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.